These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 21664472)

  • 1. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
    Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
    Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
    Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
    Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
    Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.
    Ghanbari Sevari F; Mehdizadeh A; Abbasi K; Hejazian SS; Raeisi M
    Stem Cell Res Ther; 2024 Aug; 15(1):254. PubMed ID: 39135188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.
    Narayan R; Benjamin JE; Shah O; Tian L; Tate K; Armstrong R; Xie BJ; Lowsky R; Laport G; Negrin RS; Meyer EH
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1293-1303. PubMed ID: 30951840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC; Linn YC; Hope EG; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
    Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.
    Schmeel FC; Schmeel LC; Gast SM; Schmidt-Wolf IG
    Int J Mol Sci; 2014 Aug; 15(8):14632-48. PubMed ID: 25196601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.
    Introna M; Lussana F; Algarotti A; Gotti E; Valgardsdottir R; Micò C; Grassi A; Pavoni C; Ferrari ML; Delaini F; Todisco E; Cavattoni I; Deola S; Biagi E; Balduzzi A; Rovelli A; Parma M; Napolitano S; Sgroi G; Marrocco E; Perseghin P; Belotti D; Cabiati B; Gaipa G; Golay J; Biondi A; Rambaldi A
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2070-2078. PubMed ID: 28712935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.